India, April 14 -- Anixa Biosciences, Inc. (ANIX), a biotechnology company focused on the treatment and prevention of cancer, Monday announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a new patent application covering its chimeric antigen receptor-T cell (CAR-T) technology.
The allowed claims in this patent encompass core methods and compositions that are fundamental to Anixa's innovative CAR-T approach. Anixa's CAR-T platform is specifically designed to address the long-standing challenges of applying CAR-T therapies to solid tumors, positioning the program as a potential breakthrough in immuno-oncology.
googletag.cmd.push(function() { googletag.display('div-gpt-ad-15681895...